22 results about "Prothrombin time" patented technology

The invention discloses a gymnadenia conopsea octasaccharide-decaose mixture as well as a preparation method and application thereof, and belongs to the technical field of medicines. The monosaccharide of the octasaccharide-decataccharide mixture of the gymnadenia conopsea comprises N-acetamino galactose, fucose, glucuronic acid or sugar alcohol thereof, galactose, N-acetylglucosamine, dehydrated talose and a sulfate group. The octasaccharide to decataccharide mixture of the gymnadenia conopsea disclosed by the invention can be used for remarkably prolonging the time of activating partial thromboplastin and prothrombin and effectively inhibiting endogenous and common coagulation pathways. The octasaccharide-decaose mixture of the gymnadenia conopsea can be used as a potential endogenous factor X enzyme inhibitor for preparing medicines for treating thrombotic cardiovascular diseases.

The present invention provides a traditional Chinese medicine composition for clearing heat, removing blood stasis, stopping bleeding and regulating menstruation, and a preparation method thereof, relating to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition of the present invention comprises the following components: catalpol, aucubin, β-sitosterol, emodin, chrysophanol, sanguisorba officinalis extract, Panax notoginseng saponins, septamine, cuttlefish scaly, rubiacin, typhaneuroside, and p-coumaric acid; the components synergistically work together to significantly reduce plasma prothrombin time and plasma recalcification time, and significantly reduce the whole blood viscosity, plasma viscosity, and hematocrit of rats with blood stasis syndrome. The traditional Chinese medicine composition of the present invention is used in the preparation of drugs for menstrual disorders or menstrual bleeding and metrorrhagia, and has a significant therapeutic effect on irregular menstruation, excessive menstrual bleeding, or metrorrhagia.

The invention provides a Kawasaki disease coronary artery disease risk dynamic prediction algorithm and an automatic upgrading system. The Kawasaki disease coronary artery lesion risk dynamic prediction algorithm and the automatic upgrading system comprise the following steps: a, acquiring clinical data of a Kawasaki disease child patient, including data of disease date, sex, month age, serum sodium level, D dimer, erythrocyte distribution width, prothrombin time and C-reactive protein biomarker; according to the Kawasaki disease coronary artery disease risk dynamic prediction algorithm and the automatic upgrading system, through combination of clinical features and gene data of Kawasaki disease children patients, a plurality of machine learning algorithms are used, and an efficient and accurate CAL risk prediction model is constructed. The model combines a plurality of key clinical indexes such as serum sodium level, CRP and D dimer and gene data such as SNP markers such as SIGLEC8-CEACAM18 and PPP1R1C, and the sensitivity and specificity of risk prediction are remarkably improved.

The invention belongs to the technical field of polypeptide preparation and biological pharmacy, and particularly relates to eggshell membrane polypeptide with thrombin inhibition activity and application of the eggshell membrane polypeptide. According to the invention, two polypeptides are separated and purified from an eggshell membrane, and the two polypeptides are a nonapeptide YDGQHGRVS and an octapeptide EVPPSAL respectively. Tests prove that the nonapeptide YDGQHGRVS and the octapeptide EVPPSAL have thrombin inhibition activity equivalent to that of positive control heparin sodium, and discover that the nonapeptide YDGQHGRVS prolongs the activated partial thromboplastin time and the prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSAL provided by the invention are derived from eggshell membranes, are natural in source, good in thrombin inhibition activity and high in safety, and have a good application prospect.

A fully-printed sensor chip for measuring prothrombin time of a blood sample. The sensor chip includes a pair of electrodes and a pair of contact pads, each electrically coupled to a different one of the electrodes, printed on the surface of the substrate using conductive ink materials. When a blood sample is placed on the sample chip in contact with both electrodes, an impedance of the blood sample is determined based on a measured impedance between the two contact pads. As the blood sample clots, the impedance value changes and the prothrombin time for the blood sample is determined based on a measurement time of a maximum impedance value. A resistive bridge printed on the substrate surface between the contact pads increases a baseline measurement for the sensor chip to a value within a range that is measurable by lower-cost measurement equipment.

The present invention discloses a microfluidic chip for blood coagulation detection, a blood coagulation detection device and method. The microfluidic chip is provided with a sample injection hole, an air extraction hole, a detection channel and a negative pressure constant pressure valve. The sample injection hole is connected to the inlet of the detection channel, the outlet of the detection channel is connected to the inlet of the negative pressure constant pressure valve, and the outlet of the negative pressure constant pressure valve is connected to the air extraction hole. The microfluidic chip has a simple structure, ingenious design and low manufacturing cost. The device and method are based on the above microfluidic chip. The device has a simple structure, is convenient to carry and has a low manufacturing cost. The method is simple to operate and can quickly complete the determination of prothrombin time.

The present invention discloses a pyrrolopyrimidone derivative having a structure as shown in formula I, wherein R1 is selected from C1-C3 alkoxy, halogen, cyano, n=1, 2; R2 is selected from cyano, formamide; R3 is selected from prothrombin time (PT) test, FXa in vitro inhibition test, rat in vivo antithrombotic test, and anticoagulant activity test. The pyrrolopyrimidone derivative has a significant anticoagulant effect. Therefore, the present invention also discloses the use of the pyrrolopyrimidone derivative in the preparation of a blood anticoagulant, and the blood anticoagulant is a factor Xa inhibitor.

Overt hepatic encephalopathy is a serious complication of cirrhosis and affects lipid and lipoprotein metabolism. The present invention relates to a biomarker for the prognosis of hepatic encephalopathy. The biomarker includes one or more of high-density lipoprotein cholesterol, model for end-stage liver disease score, age, gender, upper gastrointestinal bleeding, spontaneous bacterial peritonitis, overt hepatic encephalopathy grade, ascites, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol, serum creatinine, neutrophil-lymphocyte ratio, prothrombin time, and prothrombin activity level. Compared with patients with alcoholic hepatitis, liver disease, liver failure, etc. proposed in the prior art, due to the specificity of the target population, the biomarker proposed in this application can significantly improve the accuracy of the assessment of the prognosis of overt hepatic encephalopathy.

The invention relates to the technical field of biological medicine, and provides a plasma metabolite-based ALC and AH noninvasive differential diagnosis model, which is characterized in that five plasma key metabolites are taken as core indexes, and a probability calculation model is constructed through a logistic regression algorithm; the five kinds of plasma key metabolites are respectively an Ab-fubinaca metabolite 3, isocitric acid, N-docosahexaenoyl cysteine, gluconic acid-delta-lactone, and 1-palmitoyl-2-linoleyl phosphatidylethanolamine. The invention further provides a construction method and application of the model. According to the method, five key plasma metabolites with remarkable difference between AH and ALC are screened, modeling is carried out in combination with a logistic regression algorithm, or a multi-parameter model is constructed by further integrating prothrombin time, so that accurate non-invasive efficient identification of AH and ALC is realized.

The present application belongs to the technical field of polypeptide preparation and biopharmacy, and particularly relates to eggshell membrane polypeptides with thrombin inhibitory activity and application thereof. Two polypeptides are obtained by separation and purification from eggshell membranes, which are nonapeptide YDGQHGRVS and octapeptide EVPPSPAL. It is proved by experiments that the nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL have thrombin inhibitory activity equivalent to that of the positive control heparin sodium, and it is found that the nonapeptide YDGQHGRVS prolongs activated partial thromboplastin time and prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL provided by the present application are derived from eggshell membranes, are natural in origin, have good thrombin inhibitory activity, high safety, and have good application prospect.

The dominant hepatic encephalopathy is a serious complication of liver cirrhosis and affects lipid and lipoprotein metabolism. The invention relates to a biomarker for prognosis of hepatic encephalopathy. The biomarkers comprise high-density lipoprotein cholesterol, an end-stage liver disease model score, age, gender, upper gastrointestinal hemorrhage, spontaneous bacterial peritonitis, dominant hepatic encephalopathy grading, ascites, aspartic transaminase, glutamic-pyruvic transaminase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol and serum creatinine. The specific value of neutrophil to lymphocyte, the prothrombin time and the prothrombin activity level are one or more. Compared with patients with alcoholic hepatitis, liver diseases, hepatic failure and the like in the prior art, the marker provided by the invention can remarkably improve the evaluation accuracy of the prognosis of the dominant hepatic encephalopathy due to the specificity of people.

The invention provides application of a blood coagulation four-item detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent in preparation of a diabetic microangiopathy detection kit and the kit, and relates to the technical field of medical biology. The research finds that the microangiopathy of the T2DM patient is obviously associated with the four blood coagulation items, the plasma D dimer and the AT-III level, and the four blood coagulation items, the plasma D dimer and the AT-III all cause independent influence factors of the microangiopathy, so that the risk of the microangiopathy of the T2DM patient can be predicted by detecting related indexes clinically; the clinical auxiliary diagnosis value is relatively high; further, prothrombin time detection results, activated partial thromboplastin time detection results, thrombin time detection results and fibrinogen detection results can be obtained on the basis of a four-item blood coagulation detection reagent, a plasma D dimer detection reagent and an AT-III detection reagent; determining the risk of the diabetic microangiopathy according to at least one of a blood plasma D dimer detection result and an antithrombin III detection result.

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.

The present invention discloses a prothrombin time detection reagent and a preparation method thereof. Among them, the prothrombin time detection reagent is prepared from rabbit brain powder, a solvent, sodium chloride, a surfactant, a metal salt, a reducing agent, and calcium chloride. It can effectively remove coagulation factor VII, so that the prepared thromboplastin does not contain coagulation factor VII, making the prepared prothrombin time detection reagent highly sensitive to coagulation factor VII, ensuring the detection accuracy and improving its actual use effect.

The present invention relates to the field of medical detection, and specifically to a portable device for prothrombin time detection. The prothrombin time detection device includes a detection area fixed with aggregation-induced luminescence carbon dots, and the detection area is used to receive plasma; the aggregation-induced luminescence carbon dots are synthesized by the following method: dithiosalicylic acid or citric acid is mixed with triethylenetetramine or tetraethylenepentamine, and then obtained by reaction. The carbon dots of this scheme have good biocompatibility and viscosity response characteristics. The plasma sample activates the exogenous coagulation pathway under the action of coagulation reagents. Under the action of continuous excitation light, the aggregation-induced luminescence carbon dots generate a fluorescence-time curve, and its emitted light produces a red shift phenomenon, thereby determining and calculating the prothrombin time. This technical scheme can solve the technical problems of the prothrombin time detection device of the prior art that the detection accuracy and stability are not ideal due to its reliance on electrochemical detection methods, and has an ideal application and promotion prospect.

A hysteroscopic fluid management system includes a saline source with an electrolyte concentration, at least one pressure mechanism for circulating saline to and from a targeted site and through a filter having filter characteristics back to the source, and a controller. The controller provides a saline inflow in a first flow path to the site and a saline outflow in a second flow path from the site through the filter and back to the source at a controlled flow rate. A diagnostic or therapeutic procedure is performed at the site in the presence of the saline. The filter characteristics and the controlled flow rate are selected to (1) cause substantially no change in the electrolyte concentration in the saline, (2) to prevent hemolysis of greater than 5% of filtered red blood cells exposed to the saline, and / or (3) to minimize effect on prothrombin time of plasma exposed to the filter.

The invention discloses an in-vitro sample detection data-based decompensated liver cirrhosis risk assessment method and a related device, and relates to the technical field of liver cirrhosis condition assessment. The method comprises the following steps: acquiring in-vitro detection sample data corresponding to a to-be-assessed blood sample, the in-vitro detection sample data comprises sCD146, prothrombin time, serum albumin and platelet count; performing data preprocessing on the in-vitro detection sample data, namely generating a serum albumin grade variable ALBgrade based on a preset grading threshold value according to the numerical value of the serum albumin; inputting the processed feature data into a pre-trained binary Logistic regression model, and outputting a decompensated liver cirrhosis risk value corresponding to the to-be-evaluated blood sample; the decompensated liver cirrhosis risk value is a prediction probability P output by the binary Logistic regression model. The method can effectively improve the evaluation accuracy of decompensated liver cirrhosis.

The invention discloses an extraction and separation method of anise polysaccharide with anticoagulant activity. The method comprises the following steps: crushing fresh anise, extracting with hot water, concentrating a water extract, and adding ethanol for precipitation to obtain crude polysaccharide; removing protein by adopting a Sevage method; and dialyzing to remove small molecular impurities, and freeze-drying to obtain the purified anise polysaccharide. The molecular weight of the polysaccharide is about 72.053 kDa. In-vitro coagulation experiments show that the polysaccharide can significantly prolong prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) and reduce the content of fibroblast egg (FIB) white, and shows significant anticoagulant activity. The star anise polysaccharide provided by the invention can be used for preparing anticoagulant drugs, and has the advantages of wide raw material source, simple extraction process, definite activity and the like.

The invention discloses a method for predicting the lactic acid rise risk of a patient with sepsis with acute lung injury, and the method is to construct a model for predicting the lactic acid rise risk of the patient with sepsis with acute lung injury, and the model comprises the following indexes: chronic obstructive pulmonary disease, anion gap (AG), artery pH and prothrombin time (PT). The prediction method provided by the invention has relatively good distinction degree and accuracy for predicting the lactic acid rise risk of the sepsis with acute lung injury ICU patient, has relatively high practicability and applicability clinically, and is helpful for a clinician to early identify the sepsis with acute lung injury ICU patient with high risk of lactic acid rise; corresponding means are timely adopted for treatment intervention, so that the pain of the patient is relieved, the life quality of the patient is improved, and the application prospect is wide.

The present application relates to the field of machine learning, in particular to a blood sample classification method and system for coagulation index detection based on MAML and spatial transformation, mainly using a spatial transformation module to classify coagulation indexes, the specific steps comprising: obtaining the curve images of prothrombin time (PT) and thrombin time (TT) samples, extracting features and creating a training set and a test set; inputting the training set images into a module combining spatial transformation and convolution network to generate processed images; then updating parameters using gradient descent of the training model, reconstructing a spatial transformation coagulation index classification model; setting hyperparameters for the abnormal coagulation index classification model; finding the optimal model training process through model training and iterative testing to realize the classification of coagulation indexes. The present application uses MAML algorithm and spatial transformation to gradually optimize a small number of samples to achieve good generalization ability, and combines neural network structure and learning algorithm, which has wide applicability and flexibility.

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.

The invention discloses a model for early prediction of acute kidney injury risk after a sepsis patient is transferred into ICU based on clinical variables and immune inflammation indicators, and an immune-clinical model is established by adopting an XGBoost algorithm based on data of 1551 domestic sepsis patients in 24 hours after the sepsis patient is transferred into the ICU so as to predict the risk of SA-AKI of the patient. The model integrates five clinical variables including procalcitonin, APACHE II, SOFA score, gender and prothrombin time and four immune inflammation indexes including IgA, complement C3, Nave CD4 + T% and CD28 + CD4 + T%, the average ROC-AUC value is 0.914, an SHAP method is introduced to generate a feature importance map and an individual prediction interpretation map, the contribution degree of each index to risk prediction of a specific patient can be visually displayed, the cause of SA-AKI of the patient can be explained, and the risk of the specific patient can be predicted. Therefore, doctors can take targeted measures preventively.